The US Federal Trade Commission has stepped up antitrust enforcement in life sciences by seeking to block acquisitions led by Illumina and Amgen, with more deals at risk. Endpoints News will examine the origins, impacts and likely legacy of these antitrust policies.
Jeny Maier guides major corporations through large, strategic M&A transactions, using her significant experience to advise on pre-merger notification requirements and substantive competitive issues. Jeny helps clients navigate antitrust issues throughout the life cycle of a transaction, from initial risk analysis and due diligence, to negotiating merger agreement terms, through antitrust agency review, investigation and, where needed, remedies. She also regularly counsels clients who are third parties contacted by the antitrust agencies in connection with merger investigations. Described in Who’s Who Legal as a “great competition lawyer with strong expertise in merger cases” and the “knowledge and ability to provide clear and prescient insight” in to the competition world, Jeny is a sought-after antitrust advocate.
James A. Fishkin combines extensive government and private sector experience within his practice, which focuses on FTC and DOJ merger investigations covering a wide range of industries, including retail, consumer and food products, life sciences and healthcare, travel, chemicals and industrial gas, internet, and ESG issues. He has been a key participant in several of the most significant litigated antitrust cases that have set important precedents, including representing Whole Foods Market, Inc. in FTC v. Whole Foods Market, Inc. and PeroxyChem in FTC v. RAG-Stiftung (Evonik/PeroxyChem), and representing the Federal Trade Commission in FTC v. Staples, Inc. and FTC v. H.J. Heinz Co. He also served as the court-appointed Divestiture Trustee on behalf of the Department of Justice for the Grupo Bimbo/Sara Lee bread merger.
Patricia Danzon is the Celia Moh Professor Emeritus at The Wharton School, University of Pennsylvania. Professor Danzon received a B.A. from Oxford University, England, and a Ph.D. in Economics from the University of Chicago. She has held faculty positions at Duke University and the University of Chicago. Professor Danzon is an internationally recognized expert in the fields of economics of health care, the biopharmaceutical industry, and insurance. She is a member of the National Academy of Medicine and the National Academy of Social Insurance, and a Research Associate at the National Bureau of Economic Research. She has served as a consultant to many governmental agencies, NGOs and private corporations in the US and internationally. Professor Danzon has served on the Board of Directors of Medarex, Inc., the Policy and Global Affairs Board of the National Academy of Sciences, and the Policy Board of the Office of Health Economics in London.
Jared Whitlock is the features editor at Endpoints. Previously a freelance journalist and MIT knight science journalism fellow in fall 2021, his work has appeared in publications like WIRED, STAT and The New York Times. Prior to this, he was a biotech, healthcare and special projects reporter at The San Diego Business Journal. When not fussing over words, he can be find surfing at various San Diego beaches.